Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance ...

In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...